ClinicalTrials.gov record
Not yet recruiting Phase 2 Interventional

NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy

ClinicalTrials.gov ID: NCT07227909

Public ClinicalTrials.gov record NCT07227909. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 1:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT07227909
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
M.D. Anderson Cancer Center
Other
Enrollment
83 participants

Conditions and interventions

Interventions

  • Psilocybin (drug) Drug
  • Standard of Care (SOC) Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 3, 2026
Primary completion
Jan 30, 2029
Completion
Jan 30, 2031
Last update posted
Apr 15, 2026

2026 – 2031

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
MD Anderson Cancer Center Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07227909, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 15, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07227909 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →